Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023
For the six months, sales was USD 0.118129 million compared to USD 0.117433 million a year ago. Revenue was USD 0.118129 million compared to USD 0.117434 million a year ago. Net income was USD 1.58 million compared to net loss of USD 64.44 million a year ago. Basic earnings per share from continuing operations was USD 0.41 compared to basic loss per share from continuing operations of USD 21.31 a year ago.